RevBio has received approval from the US Food and Drug Administration (FDA) to initiate a pilot dental clinical trial evaluating the safety and efficacy of
RevBio, Inc. announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental
The United States Patent and Trademark Office recently issued patent 12,178,937, entitled “Compositions and Methods for Adhesion to Surfaces,” which constitutes the 10th U.S. patent
RevBio announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL
RevBio announced that it has received approval from the U.S. Food and Drug Administration to commence a 20-patient clinical trial to assess the safety and
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental
RevBio announced that it has received a strategic investment from Pacific Dental Services (PDS) to support the clinical development of its bone adhesive biomaterial for
